Pfizer (PFE) Analysts Show Caution Amid 50% Stock Decline

Currently, only 2 out of 29 analysts rate Pfizer (PFE) as strong buy, while over 60% suggest a cautious outlook with ratings of hold, underperform, or sell. The stock has declined more than 50% from its 2021 peak. Patent expirations for key drugs like Eliquis and Vyndaqel are expected to impact revenues significantly by 2028. Despite these challenges, Pfizer maintains a dividend yield of 6.6%, much higher than the market average of 1.1%. The company continues efforts in drug development, including acquiring a promising GLP-1 candidate after dropping its own.